Thus, these findings indicated that multitargeted therapy toward PI3K and mTOR might serve as an efficient treatment for those T-ALL patients that display upregulation of PI3K/Akt/mTOR signaling [231]. Here, PIK3CD is linked to acute lymphoblastic leukemia.